Compare WING & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WING | NUVL |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.1B |
| IPO Year | 2015 | 2021 |
| Metric | WING | NUVL |
|---|---|---|
| Price | $265.12 | $103.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 15 |
| Target Price | ★ $342.12 | $135.00 |
| AVG Volume (30 Days) | 559.1K | ★ 588.5K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | ★ 79.44 | N/A |
| EPS | ★ 6.14 | N/A |
| Revenue | ★ $682,980,000.00 | N/A |
| Revenue This Year | $13.82 | N/A |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | $43.25 | ★ N/A |
| Revenue Growth | ★ 15.55 | N/A |
| 52 Week Low | $204.00 | $55.54 |
| 52 Week High | $388.14 | $113.02 |
| Indicator | WING | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 48.27 |
| Support Level | $259.00 | $100.19 |
| Resistance Level | $282.00 | $107.51 |
| Average True Range (ATR) | 13.70 | 4.89 |
| MACD | -0.93 | -0.41 |
| Stochastic Oscillator | 31.18 | 36.14 |
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,932 global stores at the end of the third quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.